{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T18:02:04Z","timestamp":1785261724112,"version":"3.55.0"},"posted":{"date-parts":[[2026,7,28]]},"group-title":"In Review","reference-count":96,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,5,8]]},"abstract":"<title>Abstract<\/title>\n                <p>Programmed cell death protein 1 (PD-1) and programmed death ligand-1 (PD-L1) are immune checkpoint proteins involved in tumour evasion of immune suppression. Inhibitors of these proteins are approved to treat cancer patients restricted by criteria such as site and immunologically \u2018hot\u2019 tumour features. To assess their repurposing potential to additional cancer patient populations, we used a Mendelian randomisation approach to investigate the effects of germline proxied plasma PD-1 or PD-L1 lowering on all-cause or cancer-specific mortality risk after diagnosis of cancers with (breast, colorectal, lung, melanoma) or without (ovarian, prostate) PD-1 and PD-L1 inhibitor approvals. Across the four studied cancers with current PD-1\/L1 inhibitor approvals, hazard ratios (HRs) for mortality [95% confidence intervals] per standard deviation decrease in germline proxied plasma protein levels were PD-1:0.91 [0.84\u20130.98]; PD-L1:0.98 [0.92\u20131.05]. This suggests failure of the PD-L1 instrument to recapitulate known pharmaceutical effects of PD-L1 inhibition, potentially due to germline proxies not robustly reflecting tumour PD-L1 mechanisms.  There was evidence to support PD-1 inhibitor repurposing for a novel indication, ovarian cancer treatment (HR\u2009=\u20090.88 [0.78\u20130.99]), and to broader colorectal (HR\u2009=\u20090.84 [0.71-1.00]) and early-stage lung (HR\u2009=\u20090.75 [0.61\u20130.93]) cancer populations than current approvals. Where possible, methodological considerations were addressed but findings should be interpreted with caution.<\/p>","DOI":"10.21203\/rs.3.rs-9656350\/v1","type":"posted-content","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:38:33Z","timestamp":1785260313000},"source":"Crossref","is-referenced-by-count":0,"title":["Investigating the repurposing potential of immune checkpoint inhibition for cancer treatment using Mendelian randomisation"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8034-2070","authenticated-orcid":false,"given":"Tessa","family":"Bate","sequence":"first","affiliation":[{"name":"University of Bristol"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Dong","sequence":"additional","affiliation":[{"name":"Dalla Lana School of Public Health, University of Toronto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2484-151X","authenticated-orcid":false,"given":"Yuxi","family":"Liu","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Seviiri","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0184-7732","authenticated-orcid":false,"given":"M. Catherine","family":"Brown","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0821-1112","authenticated-orcid":false,"given":"Joshua","family":"Atkins","sequence":"additional","affiliation":[{"name":"University of Oxford"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1932-7463","authenticated-orcid":false,"given":"Karl","family":"Smith-Byrne","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology Unit, University of Oxford"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6316-5484","authenticated-orcid":false,"given":"The Practical","family":"Consortium","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayjean","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4303-8821","authenticated-orcid":false,"given":"Matthew","family":"Law","sequence":"additional","affiliation":[{"name":"QIMR Berghofer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2603-6509","authenticated-orcid":false,"given":"Mark","family":"Iles","sequence":"additional","affiliation":[{"name":"University of Leeds"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadis","family":"Ghajari","sequence":"additional","affiliation":[{"name":"QIMR Berghofer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serigne","family":"Lo","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, University of Sydney"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7980-4620","authenticated-orcid":false,"given":"Alexander","family":"Gusev","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Vanderwerff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Zoellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Liu","sequence":"additional","affiliation":[{"name":"University Health Network \/ Princess Margaret Cancer Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[{"name":"University Health Network, Toronto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7992-7719","authenticated-orcid":false,"given":"Richard","family":"Martin","sequence":"additional","affiliation":[{"name":"University of Bristol"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Yarmolinsky","sequence":"additional","affiliation":[{"name":"Imperial College of London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Haycock","sequence":"additional","affiliation":[{"name":"University of Bristol"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"International Lung Cancer Consortium","family":"(ILCCO)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"3","key":"ref1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray, F., et al., Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 2024. 74(3): p. 229\u2013263."},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2174\/1568009615666141229152812","article-title":"Potential anti-cancer drugs commonly used for other indications","volume":"15","author":"Hanusova V","year":"2015","unstructured":"Hanusova, V., et al., Potential anti-cancer drugs commonly used for other indications. Curr Cancer Drug Targets, 2015. 15(1): p. 35\u201352.","journal-title":"Curr Cancer Drug Targets"},{"issue":"6","key":"ref3","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/ije\/dyx207","article-title":"Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities","volume":"46","author":"Walker VM","year":"2017","unstructured":"Walker, V.M., et al., Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities. International Journal of Epidemiology, 2017. 46(6): p. 2078\u20132089.","journal-title":"International Journal of Epidemiology"},{"issue":"9","key":"ref4","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S1470-2045(20)30424-1","article-title":"Drug repurposing for cancer treatments: a well-intentioned, but misguided strategy","volume":"21","author":"Tran AA","year":"2020","unstructured":"Tran, A.A. and V. Prasad, Drug repurposing for cancer treatments: a well-intentioned, but misguided strategy. The Lancet Oncology, 2020. 21(9): p. 1134\u20131136.","journal-title":"The Lancet Oncology"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-020-00213-8","article-title":"Overcoming cancer therapeutic bottleneck by drug repurposing","volume":"5","author":"Zhang Z","year":"2020","unstructured":"Zhang, Z., et al., Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduction and Targeted Therapy, 2020. 5(1): p. 113.","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan D","year":"2022","unstructured":"Hanahan, D., Hallmarks of Cancer: New Dimensions. Cancer Discov, 2022. 12(1): p. 31\u201346.","journal-title":"Cancer Discov"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-021-01056-8","article-title":"Next generation of immune checkpoint inhibitors and beyond","volume":"14","author":"Marin-Acevedo JA","year":"2021","unstructured":"Marin-Acevedo, J.A., E.O. Kimbrough, and Y. Lou, Next generation of immune checkpoint inhibitors and beyond. Journal of Hematology & Oncology, 2021. 14(1): p. 45.","journal-title":"Journal of Hematology & Oncology"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1053\/j.seminoncol.2017.06.002","article-title":"A molecular and preclinical comparison of the PD-1\u2013targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab","volume":"44","author":"Fessas P","year":"2017","unstructured":"Fessas, P., et al., A molecular and preclinical comparison of the PD-1\u2013targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Seminars in Oncology, 2017. 44(2): p. 136\u2013140.","journal-title":"Seminars in Oncology"},{"issue":"7689","key":"ref9","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst RS","year":"2018","unstructured":"Herbst, R.S., D. Morgensztern, and C. Boshoff, The biology and management of non-small cell lung cancer. Nature, 2018. 553(7689): p. 446\u2013454.","journal-title":"Nature"},{"issue":"3","key":"ref10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe AH","year":"2018","unstructured":"Sharpe, A.H. and K.E. Pauken, The diverse functions of the PD1 inhibitory pathway. Nature Reviews Immunology, 2018. 18(3): p. 153\u2013167.","journal-title":"Nature Reviews Immunology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome","volume":"8","author":"Alsaab HO","year":"2017","unstructured":"Alsaab, H.O., et al., PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Front Pharmacol, 2017. 8: p. 561.","journal-title":"Front Pharmacol"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons","volume":"20","author":"Naimi A","year":"2022","unstructured":"Naimi, A., et al., Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal, 2022. 20(1): p. 44.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1038\/s41467-025-57941-0","article-title":"Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals","volume":"16","author":"Sledge GW","year":"2025","unstructured":"Sledge, G.W., et al., Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals. Nature Communications, 2025. 16(1): p. 2646.","journal-title":"Nature Communications"},{"key":"ref14","unstructured":"United States Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue\/site agnostic indication. 2017; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication."},{"key":"ref15","unstructured":"Medicines and Healthcare products Regulatory Agency. KEYTRUDA 25 MG\/ML CONCENTRATE FOR SOLUTION FOR INFUSION: SUMMARY OF PRODUCT CHARACTERISTICS. 2025 18\/07\/2025]; Available from: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/7eef2e69c81188a6ed878409adbae676c03a5126."},{"key":"ref16","unstructured":"Medicines and Healthcare products Regulatory Agency. OPDIVO 10MG\/ML CONCENTRATE FOR SOLUTION FOR INFUSION: SUMMARY OF PRODUCT CHARACTERISTICS. 2025 18\/07\/2025]; Available from: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/8cb2b6ae0ac1ac8c24d308b869abdc35db73b2e8."},{"key":"ref17","unstructured":"Medicines and Healthcare products Regulatory Agency. LIBTAYO 350 MG CONCENTRATE FOR SOLUTION FOR INFUSION: SUMMARY OF PRODUCT CHARACTERISTICS 2025 18\/07\/2025]; Available from: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/5c12dbebe291e0d014b9f755260ed8a074394d7c."},{"key":"ref18","unstructured":"Medicines and Healthcare products Regulatory Agency. JEMPERLI 500 MG CONCENTRATE FOR SOLUTION FOR INFUSION: SUMMARY OF PRODUCT CHARACTERISTICS. 2025 18\/07\/2025]; Available from: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/ab328b28a96ed6b7d8d90ff0d05a6850d3bdef0b."},{"key":"ref19","unstructured":"Medicines and Healthcare products Regulatory Agency. TECENTRIQ 840 MG CONCENTRATE FOR SOLUTION FOR INFUSION: SUMMARY OF PRODUCT CHARACTERISTICS. 2025 18\/07\/2025]; Available from: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/ee9ca522dc92795c9f919cae119933ccbf39d39b."},{"key":"ref20","unstructured":"Medicines and Healthcare products Regulatory Agency. BAVENCIO 20 MG\/ML CONCENTRATE FOR SOLUTION FOR INFUSION: SUMMARY OF PRODUCT CHARACTERISTICS. 2025 18\/07\/2025]; Available from: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/d3de9156a3b06cc2203dd0ff74eef74cf5bef50a."},{"key":"ref21","unstructured":"Medicines and Healthcare products Regulatory Agency. IMFINZI 50 MG\/ML CONCENTRATE FOR SOLUTION FOR INFUSISON: SUMMARY OF PRODUCT CHARACTERISTICS. 2025 18\/07\/2025]; Available from: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/d3de9156a3b06cc2203dd0ff74eef74cf5bef50a."},{"key":"ref22","unstructured":"Medicines and Healthcare products Regulatory Agency. OPDIVO 600 MG SOLUTION FOR INJECTION: SUMMARY OF PRODUCT CHARACTERISTICS. 2025 18\/07\/2025]; Available from: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/d4cd0f67d7b192ced33bf6309cccd66bba6d4b03."},{"key":"ref23","unstructured":"Medicines and Healthcare products Regulatory Agency. TECENTRIQ 1,200 MG CONCENTRATE FOR SOLUTION FOR INFUSION: SUMMARY OF PRODUCT CHARACTERISTICS. 2025 18\/07\/2025]; Available from: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/5826912d63d56178b6ff24eabebcb6baf6f65058."},{"key":"ref24","unstructured":"Medicines and Healthcare products Regulatory Agency. TECENTRIQ 1,875 MG SOLUTION FOR INJECTION: SUMMARY OF PRODUCT CHARACTERISTICS. 2025 18\/07\/2025]; Available from: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/41ea671cdc333699745b94754f1bc49ebc1b6ede."},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu B","year":"2024","unstructured":"Wu, B., et al., Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther, 2024. 9(1): p. 274.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"7830","DOI":"10.1038\/s41598-021-87575-3","article-title":"Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer","volume":"11","author":"Shimada Y","year":"2021","unstructured":"Shimada, Y., et al., Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer. Scientific Reports, 2021. 11(1): p. 7830.","journal-title":"Scientific Reports"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"6952","DOI":"10.1038\/s41598-023-33128-9","article-title":"Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy","volume":"13","author":"Shin K","year":"2023","unstructured":"Shin, K., et al., Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy. Scientific Reports, 2023. 13(1): p. 6952.","journal-title":"Scientific Reports"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.annonc.2019.09.005","article-title":"Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma","volume":"31","author":"Ugurel S","year":"2020","unstructured":"Ugurel, S., et al., Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma. Annals of Oncology, 2020. 31(1): p. 144\u2013152.","journal-title":"Annals of Oncology"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s12672-023-00641-2","article-title":"Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC","volume":"14","author":"Yi L","year":"2023","unstructured":"Yi, L., et al., Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC. Discover Oncology, 2023. 14(1): p. 35.","journal-title":"Discover Oncology"},{"issue":"3","key":"ref30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11912-021-01023-z","article-title":"Statins as Potential Chemoprevention or Therapeutic Agents in Cancer: a Model for Evaluating Repurposed Drugs","volume":"23","author":"Joharatnam-Hogan N","year":"2021","unstructured":"Joharatnam-Hogan, N., et al., Statins as Potential Chemoprevention or Therapeutic Agents in Cancer: a Model for Evaluating Repurposed Drugs. Curr Oncol Rep, 2021. 23(3): p. 29.","journal-title":"Curr Oncol Rep"},{"issue":"9","key":"ref31","doi-asserted-by":"crossref","first-page":"e072087","DOI":"10.1136\/bmjopen-2023-072087","article-title":"Systematic comparison of Mendelian randomisation studies and randomised controlled trials using electronic databases","volume":"13","author":"Sobczyk MK","year":"2023","unstructured":"Sobczyk, M.K., et al., Systematic comparison of Mendelian randomisation studies and randomised controlled trials using electronic databases. BMJ Open, 2023. 13(9): p. e072087.","journal-title":"BMJ Open"},{"issue":"4","key":"ref32","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s40471-017-0128-6","article-title":"Recent Developments in Mendelian Randomization Studies","volume":"4","author":"Zheng J","year":"2017","unstructured":"Zheng, J., et al., Recent Developments in Mendelian Randomization Studies. Current Epidemiology Reports, 2017. 4(4): p. 330\u2013345.","journal-title":"Current Epidemiology Reports"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.12688\/wellcomeopenres.16544.1","article-title":"Mendelian randomization for studying the effects of perturbing drug targets","volume":"6","author":"Gill D","year":"2021","unstructured":"Gill, D., et al., Mendelian randomization for studying the effects of perturbing drug targets. Wellcome Open Res, 2021. 6: p. 16.","journal-title":"Wellcome Open Res"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"9386","DOI":"10.1038\/s41598-019-45747-2","article-title":"Interleukin-18 as a drug repositioning opportunity for inflammatory bowel disease: A Mendelian randomization study","volume":"9","author":"Mokry LE","year":"2019","unstructured":"Mokry, L.E., et al., Interleukin-18 as a drug repositioning opportunity for inflammatory bowel disease: A Mendelian randomization study. Scientific Reports, 2019. 9(1): p. 9386.","journal-title":"Scientific Reports"},{"key":"ref35","author":"Mitchell RE","year":"2022","unstructured":"Mitchell, R.E., et al., Strategies to investigate and mitigate collider bias in genetic and Mendelian randomization studies of disease progression. medRxiv, 2022: p. 2022.04.22.22274166."},{"issue":"10","key":"ref36","doi-asserted-by":"crossref","first-page":"e1006944","DOI":"10.1371\/journal.pgen.1006944","article-title":"Genetic epidemiology and Mendelian randomization for informing disease therapeutics: Conceptual and methodological challenges","volume":"13","author":"Paternoster L","year":"2017","unstructured":"Paternoster, L., K. Tilling, and G. Davey Smith, Genetic epidemiology and Mendelian randomization for informing disease therapeutics: Conceptual and methodological challenges. PLOS Genetics, 2017. 13(10): p. e1006944.","journal-title":"PLOS Genetics"},{"key":"ref37","first-page":"7","article-title":"The MR-Base platform supports systematic causal inference across the human phenome","author":"Hemani G","year":"2018","unstructured":"Hemani, G., et al., The MR-Base platform supports systematic causal inference across the human phenome. Elife, 2018. 7.","journal-title":"Elife"},{"issue":"6","key":"ref38","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0197-2456(00)00104-5","article-title":"Sample-Size Calculations for the Cox Proportional Hazards Regression Model with Nonbinary Covariates","volume":"21","author":"Hsieh FY","year":"2000","unstructured":"Hsieh, F.Y. and P.W. Lavori, Sample-Size Calculations for the Cox Proportional Hazards Regression Model with Nonbinary Covariates. Controlled Clinical Trials, 2000. 21(6): p. 552\u2013560.","journal-title":"Controlled Clinical Trials"},{"key":"ref39","author":"Qiu W","year":"2021","unstructured":"Qiu, W., et al. powerSurvEpi: Power and Sample Size Calculation for Survival Analysis of Epidemiological Studies. 2021 [cited 2024 08 March]; Available from: https:\/\/CRAN.R-project.org\/package=powerSurvEpi."},{"key":"ref40","author":"Okut H","year":"2025","unstructured":"Okut, H., Discovering Causality with Mendelian Randomization: What It Is and How to Do It, in Unraveling the Causalities of Genetic Variations - Recent Advances in Cytogenetics, H. Okut and S.K. Dey, Editors. 2025, IntechOpen: London."},{"key":"ref41","author":"Robinson JW","year":"2022","unstructured":"Robinson, J.W., et al., An efficient and robust tool for colocalisation: Pair-wise Conditional and Colocalisation (PWCoCo). bioRxiv, 2022: p. 2022.08.08.503158."},{"issue":"5\u20136","key":"ref42","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/gepi.22455","article-title":"Adjusting for collider bias in genetic association studies using instrumental variable methods","volume":"46","author":"Cai S","year":"2022","unstructured":"Cai, S., et al., Adjusting for collider bias in genetic association studies using instrumental variable methods. Genet Epidemiol, 2022. 46(5\u20136): p. 303\u2013316.","journal-title":"Genet Epidemiol"},{"issue":"1","key":"ref43","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.1038\/s41467-020-19478-2","article-title":"Collider bias undermines our understanding of COVID-19 disease risk and severity","volume":"11","author":"Griffith GJ","year":"2020","unstructured":"Griffith, G.J., et al., Collider bias undermines our understanding of COVID-19 disease risk and severity. Nature Communications, 2020. 11(1): p. 5749.","journal-title":"Nature Communications"},{"issue":"4","key":"ref44","doi-asserted-by":"crossref","DOI":"10.3390\/ph14040367","article-title":"Checkpoint Inhibitor-Induced Colitis-A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options","volume":"14","author":"Portenkirchner C","year":"2021","unstructured":"Portenkirchner, C., P. Kienle, and K. Horisberger, Checkpoint Inhibitor-Induced Colitis-A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options. Pharmaceuticals (Basel), 2021. 14(4).","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"ref45","doi-asserted-by":"crossref","first-page":"e075981","DOI":"10.1136\/bmjopen-2023-075981","article-title":"Investigating the association between genetically proxied circulating levels of immune checkpoint proteins and cancer survival: protocol for a Mendelian randomisation analysis","volume":"14","author":"Bate T","year":"2024","unstructured":"Bate, T., et al., Investigating the association between genetically proxied circulating levels of immune checkpoint proteins and cancer survival: protocol for a Mendelian randomisation analysis. BMJ Open, 2024. 14(2): p. e075981.","journal-title":"BMJ Open"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"120827","DOI":"10.1016\/j.lfs.2022.120827","article-title":"Targeting PD-1\/PD-L1 axis as new horizon for ovarian cancer therapy","volume":"306","author":"Khatoon E","year":"2022","unstructured":"Khatoon, E., et al., Targeting PD-1\/PD-L1 axis as new horizon for ovarian cancer therapy. Life Sciences, 2022. 306: p. 120827.","journal-title":"Life Sciences"},{"issue":"20","key":"ref47","doi-asserted-by":"crossref","first-page":"12067","DOI":"10.3390\/ijms232012067","article-title":"Focus on PD-1\/PD-L1 as a Therapeutic Target in Ovarian Cancer","volume":"23","author":"Dumitru A","year":"2022","unstructured":"Dumitru, A., et al., Focus on PD-1\/PD-L1 as a Therapeutic Target in Ovarian Cancer. International Journal of Molecular Sciences, 2022. 23(20): p. 12067.","journal-title":"International Journal of Molecular Sciences"},{"issue":"8","key":"ref48","doi-asserted-by":"crossref","first-page":"103666","DOI":"10.1016\/j.drudis.2023.103666","article-title":"PD-1\/PD-L1 immune checkpoint blockade in ovarian cancer: Dilemmas and opportunities","volume":"28","author":"Peng Z","year":"2023","unstructured":"Peng, Z., et al., PD-1\/PD-L1 immune checkpoint blockade in ovarian cancer: Dilemmas and opportunities. Drug Discovery Today, 2023. 28(8): p. 103666.","journal-title":"Drug Discovery Today"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1111061","DOI":"10.3389\/fphar.2023.1111061","article-title":"Efficacy and safety of PD-1\/PD-L1 inhibitors in the treatment of recurrent and refractory ovarian cancer: A systematic review and a meta-analysis","volume":"14","author":"Zeng S","year":"2023","unstructured":"Zeng, S., et al., Efficacy and safety of PD-1\/PD-L1 inhibitors in the treatment of recurrent and refractory ovarian cancer: A systematic review and a meta-analysis. Front Pharmacol, 2023. 14: p. 1111061.","journal-title":"Front Pharmacol"},{"issue":"1","key":"ref50","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13048-021-00862-5","article-title":"Efficacy of PD-1\/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis","volume":"14","author":"Zhu J","year":"2021","unstructured":"Zhu, J., L. Yan, and Q. Wang, Efficacy of PD-1\/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis. Journal of Ovarian Research, 2021. 14(1): p. 112.","journal-title":"Journal of Ovarian Research"},{"issue":"20","key":"ref51","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1080\/14796694.2025.2530378","article-title":"Efficacy of PD-1\/PDL-1 inhibitors for ovarian cancer: a systematic review and network meta-analysis","volume":"21","author":"Ahmadi N","year":"2025","unstructured":"Ahmadi, N., et al., Efficacy of PD-1\/PDL-1 inhibitors for ovarian cancer: a systematic review and network meta-analysis. Future Oncology, 2025. 21(20): p. 2637\u20132647.","journal-title":"Future Oncology"},{"issue":"4","key":"ref52","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/ije\/dyz236","article-title":"Comparison with randomized controlled trials as a strategy for evaluating instruments in Mendelian randomization","volume":"49","author":"Gill D","year":"2019","unstructured":"Gill, D., et al., Comparison with randomized controlled trials as a strategy for evaluating instruments in Mendelian randomization. International Journal of Epidemiology, 2019. 49(4): p. 1404\u20131406.","journal-title":"International Journal of Epidemiology"},{"issue":"23","key":"ref53","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1158\/1078-0432.CCR-15-0632","article-title":"Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium","volume":"21","author":"Johnatty SE","year":"2015","unstructured":"Johnatty, S.E., et al., Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clin Cancer Res, 2015. 21(23): p. 5264\u201376.","journal-title":"Clin Cancer Res"},{"key":"ref54","article-title":"Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers","author":"Tan PB","year":"2025","unstructured":"Tan, P.B., et al., Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers. Nature, 2025.","journal-title":"Nature"},{"issue":"1","key":"ref55","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41598-021-03945-x","article-title":"Genome-wide association study identifies tumor anatomical site-specific risk variants for colorectal cancer survival","volume":"12","author":"Labadie JD","year":"2022","unstructured":"Labadie, J.D., et al., Genome-wide association study identifies tumor anatomical site-specific risk variants for colorectal cancer survival. Sci Rep, 2022. 12(1): p. 127.","journal-title":"Sci Rep"},{"issue":"2","key":"ref56","first-page":"e2400077","article-title":"Immune Checkpoint Blockade Therapies for Colorectal Cancer: Current Strategies and Emerging Approaches","volume":"2025","author":"Pum K","unstructured":"Pum, K., et al., Immune Checkpoint Blockade Therapies for Colorectal Cancer: Current Strategies and Emerging Approaches. JCO Oncology Advances, 2025(2): p. e2400077.","journal-title":"JCO Oncology Advances"},{"issue":"4","key":"ref57","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041022","article-title":"Challenges and Therapeutic Opportunities in the dMMR\/MSI-H Colorectal Cancer Landscape","volume":"15","author":"Mulet-Margalef N","year":"2023","unstructured":"Mulet-Margalef, N., et al., Challenges and Therapeutic Opportunities in the dMMR\/MSI-H Colorectal Cancer Landscape. Cancers (Basel), 2023. 15(4).","journal-title":"Cancers (Basel)"},{"issue":"1","key":"ref58","first-page":"1807929","article-title":"Epidemiology of Microsatellite Instability High (MSI-H) and Deficient Mismatch Repair (dMMR) in Solid Tumors: A Structured Literature Review","volume":"2020","author":"Lorenzi M","year":"2020","unstructured":"Lorenzi, M., et al., Epidemiology of Microsatellite Instability High (MSI-H) and Deficient Mismatch Repair (dMMR) in Solid Tumors: A Structured Literature Review. Journal of Oncology, 2020. 2020(1): p. 1807929.","journal-title":"Journal of Oncology"},{"issue":"3","key":"ref59","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cllc.2025.01.006","article-title":"Immunotherapy for Early-Stage Non\u2013Small Cell Lung Cancer: A Practical Guide of Current Controversies","volume":"26","author":"Phillips WJ","year":"2025","unstructured":"Phillips, W.J., et al., Immunotherapy for Early-Stage Non\u2013Small Cell Lung Cancer: A Practical Guide of Current Controversies. Clinical Lung Cancer, 2025. 26(3): p. 179\u2013190.","journal-title":"Clinical Lung Cancer"},{"issue":"7982","key":"ref60","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","article-title":"Plasma proteomic associations with genetics and health in the UK Biobank","volume":"622","author":"Sun BB","year":"2023","unstructured":"Sun, B.B., et al., Plasma proteomic associations with genetics and health in the UK Biobank. Nature, 2023. 622(7982): p. 329\u2013338.","journal-title":"Nature"},{"issue":"2","key":"ref61","doi-asserted-by":"crossref","first-page":"e1003897","DOI":"10.1371\/journal.pmed.1003897","article-title":"Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysis","volume":"19","author":"Yarmolinsky J","year":"2022","unstructured":"Yarmolinsky, J., et al., Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysis. PLOS Medicine, 2022. 19(2): p. e1003897.","journal-title":"PLOS Medicine"},{"issue":"1","key":"ref62","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s13238-017-0412-8","article-title":"Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab","volume":"9","author":"Tan S","year":"2018","unstructured":"Tan, S., et al., Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab. Protein Cell, 2018. 9(1): p. 135\u2013139.","journal-title":"Protein Cell"},{"issue":"12","key":"ref63","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.3390\/biomedicines10123154","article-title":"The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy","volume":"10","author":"Jeong T-J","year":"2022","unstructured":"Jeong, T.-J., et al., The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy. Biomedicines, 2022. 10(12): p. 3154.","journal-title":"Biomedicines"},{"issue":"1","key":"ref64","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s43586-021-00092-5","article-title":"Mendelian randomization","volume":"2","author":"Sanderson E","year":"2022","unstructured":"Sanderson, E., et al., Mendelian randomization. Nature Reviews Methods Primers, 2022. 2(1): p. 6.","journal-title":"Nature Reviews Methods Primers"},{"issue":"6","key":"ref65","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1093\/ije\/dyx034","article-title":"MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data","volume":"46","author":"Yavorska OO","year":"2017","unstructured":"Yavorska, O.O. and S. Burgess, MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. International Journal of Epidemiology, 2017. 46(6): p. 1734\u20131739.","journal-title":"International Journal of Epidemiology"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"252","DOI":"10.12688\/wellcomeopenres.16374.2","article-title":"MendelianRandomization v0.5.0: updates to an R package for performing Mendelian randomization analyses using summarized data","volume":"5","author":"Broadbent JR","year":"2020","unstructured":"Broadbent, J.R., et al., MendelianRandomization v0.5.0: updates to an R package for performing Mendelian randomization analyses using summarized data. Wellcome Open Res, 2020. 5: p. 252.","journal-title":"Wellcome Open Res"},{"issue":"6","key":"ref67","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/gepi.21645","article-title":"Power and sample size calculations for SNP association studies with censored time-to-event outcomes","volume":"36","author":"Owzar K","year":"2012","unstructured":"Owzar, K., et al., Power and sample size calculations for SNP association studies with censored time-to-event outcomes. Genet Epidemiol, 2012. 36(6): p. 538\u201348.","journal-title":"Genet Epidemiol"},{"key":"ref68","unstructured":"NHS England. Cancer Survival in England, cancers diagnosed 2016 to 2020, followed up to 2021. 2023 [cited 2024 08 March]; Available from: https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/cancer-survival-in-england\/cancers-diagnosed-2016-to-2020-followed-up-to-2021\/."},{"key":"ref69","unstructured":"Cancer Intelligence Team at Cancer Research UK. Cancer Statistics Data Hub. [cited 2024 08 March]; Available from: https:\/\/crukcancerintelligence.shinyapps.io\/CancerStatsDataHub\/."},{"issue":"6","key":"ref70","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0197-2456(00)00104-5","article-title":"Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates","volume":"21","author":"Hsieh FY","year":"2000","unstructured":"Hsieh, F.Y. and P.W. Lavori, Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin Trials, 2000. 21(6): p. 552\u201360.","journal-title":"Control Clin Trials"},{"issue":"1","key":"ref71","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13058-021-01450-7","article-title":"Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment","volume":"23","author":"Morra A","year":"2021","unstructured":"Morra, A., et al., Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Research, 2021. 23(1): p. 86.","journal-title":"Breast Cancer Research"},{"issue":"2","key":"ref72","doi-asserted-by":"crossref","DOI":"10.1093\/carcin\/bgaf031","article-title":"Genome-wide association study of early-stage non-small cell lung cancer prognosis: a pooled analysis in the International Lung Cancer Consortium","volume":"46","author":"Dong M","year":"2025","unstructured":"Dong, M., et al., Genome-wide association study of early-stage non-small cell lung cancer prognosis: a pooled analysis in the International Lung Cancer Consortium. Carcinogenesis, 2025. 46(2).","journal-title":"Carcinogenesis"},{"issue":"1","key":"ref73","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1186\/s12967-022-03613-2","article-title":"Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting","volume":"20","author":"Seviiri M","year":"2022","unstructured":"Seviiri, M., et al., Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting. J Transl Med, 2022. 20(1): p. 403.","journal-title":"J Transl Med"},{"issue":"11","key":"ref74","doi-asserted-by":"crossref","first-page":"e1007081","DOI":"10.1371\/journal.pgen.1007081","article-title":"Orienting the causal relationship between imprecisely measured traits using GWAS summary data","volume":"13","author":"Hemani G","year":"2017","unstructured":"Hemani, G., K. Tilling, and G. Davey Smith, Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLOS Genetics, 2017. 13(11): p. e1007081.","journal-title":"PLOS Genetics"},{"key":"ref75","author":"Purcell S","unstructured":"Purcell, S. and C. Chang. PLINK v1.90. [cited 2024 06 March]; Available from: www.cog-genomics.org\/plink\/1.9\/."},{"issue":"1","key":"ref76","doi-asserted-by":"crossref","DOI":"10.1186\/s13742-015-0047-8","article-title":"Second-generation PLINK: rising to the challenge of larger and richer datasets","volume":"4","author":"Chang CC","year":"2015","unstructured":"Chang, C.C., et al., Second-generation PLINK: rising to the challenge of larger and richer datasets. GigaScience, 2015. 4(1).","journal-title":"GigaScience"},{"issue":"3","key":"ref77","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1086\/519795","article-title":"PLINK: a tool set for whole-genome association and population-based linkage analyses","volume":"81","author":"Purcell S","year":"2007","unstructured":"Purcell, S., et al., PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet, 2007. 81(3): p. 559\u201375.","journal-title":"Am J Hum Genet"},{"key":"ref78","author":"Scheinin I","year":"2025","unstructured":"Scheinin I, K.M., Jagerroos V, Parkkinen J, Tikkanen E, W\u00fcrtz P, Kangas A.,, ggforestplot: Forestplots of Measures of Effects and Their Confidence Intervals R package. 2025."},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.4530893","author":"England Genomics","year":"2025","unstructured":"Genomics England, National Genomic Research Library. 2025, figshare:https:\/\/doi.org\/10.6084\/m9.figshare.4530893."},{"issue":"5","key":"ref80","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/bjc.2015.245","article-title":"Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium","volume":"113","author":"Nagle CM","year":"2015","unstructured":"Nagle, C.M., et al., Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. British Journal of Cancer, 2015. 113(5): p. 817\u2013826.","journal-title":"British Journal of Cancer"},{"issue":"6","key":"ref81","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41588-020-0609-2","article-title":"Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses","volume":"52","author":"Zhang H","year":"2020","unstructured":"Zhang, H., et al., Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nat Genet, 2020. 52(6): p. 572\u2013581.","journal-title":"Nat Genet"},{"issue":"1","key":"ref82","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41588-022-01222-9","article-title":"Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries","volume":"55","author":"Fernandez-Rozadilla C","year":"2023","unstructured":"Fernandez-Rozadilla, C., et al., Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries. Nat Genet, 2023. 55(1): p. 89\u201399.","journal-title":"Nat Genet"},{"issue":"9","key":"ref83","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/ng.3373","article-title":"Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma","volume":"47","author":"Law MH","year":"2015","unstructured":"Law, M.H., et al., Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. Nat Genet, 2015. 47(9): p. 987\u2013995.","journal-title":"Nat Genet"},{"issue":"5","key":"ref84","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/ng.3826","article-title":"Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer","volume":"49","author":"Phelan CM","year":"2017","unstructured":"Phelan, C.M., et al., Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet, 2017. 49(5): p. 680\u2013691.","journal-title":"Nat Genet"},{"issue":"10","key":"ref85","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/ng.3094","article-title":"A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer","volume":"46","author":"Al Olama AA","year":"2014","unstructured":"Al Olama, A.A., et al., A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet, 2014. 46(10): p. 1103\u20139.","journal-title":"Nat Genet"},{"issue":"1","key":"ref86","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41467-022-28119-9","article-title":"A robust method for collider bias correction in conditional genome-wide association studies","volume":"13","author":"Mahmoud O","year":"2022","unstructured":"Mahmoud, O., et al., A robust method for collider bias correction in conditional genome-wide association studies. Nature Communications, 2022. 13(1): p. 619.","journal-title":"Nature Communications"},{"issue":"7726","key":"ref87","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","article-title":"The UK Biobank resource with deep phenotyping and genomic data","volume":"562","author":"Bycroft C","year":"2018","unstructured":"Bycroft, C., et al., The UK Biobank resource with deep phenotyping and genomic data. Nature, 2018. 562(7726): p. 203\u2013209.","journal-title":"Nature"},{"issue":"3","key":"ref88","doi-asserted-by":"crossref","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","article-title":"UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age","volume":"12","author":"Sudlow C","year":"2015","unstructured":"Sudlow, C., et al., UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med, 2015. 12(3): p. e1001779.","journal-title":"PLoS Med"},{"issue":"6","key":"ref89","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.cell.2018.10.022","article-title":"Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression","volume":"175","author":"Schmiedel BJ","year":"2018","unstructured":"Schmiedel, B.J., et al., Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression. Cell, 2018. 175(6): p. 1701\u20131715.e16.","journal-title":"Cell"},{"issue":"D1","key":"ref90","doi-asserted-by":"crossref","first-page":"D971","DOI":"10.1093\/nar\/gkx861","article-title":"PancanQTL: systematic identification of cis-eQTLs and trans-eQTLs in 33 cancer types","volume":"46","author":"Gong J","year":"2017","unstructured":"Gong, J., et al., PancanQTL: systematic identification of cis-eQTLs and trans-eQTLs in 33 cancer types. Nucleic Acids Research, 2017. 46(D1): p. D971\u2013D976.","journal-title":"Nucleic Acids Research"},{"key":"ref91","author":"Hemani G","year":"2025","unstructured":"Hemani, G., gwasvcf: Tools for Dealing with GWAS Summary Data in VCF Format R package. 2025."},{"issue":"6","key":"ref92","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/ng.2653","article-title":"The Genotype-Tissue Expression (GTEx) project","volume":"45","author":"Lonsdale J","year":"2013","unstructured":"Lonsdale, J., et al., The Genotype-Tissue Expression (GTEx) project. Nature Genetics, 2013. 45(6): p. 580\u2013585.","journal-title":"Nature Genetics"},{"issue":"1","key":"ref93","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin X","year":"2024","unstructured":"Lin, X., et al., Regulatory mechanisms of PD-1\/PD-L1 in cancers. Molecular Cancer, 2024. 23(1): p. 108.","journal-title":"Molecular Cancer"},{"issue":"1","key":"ref94","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13045-022-01242-2","article-title":"Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation","volume":"15","author":"Wu M","year":"2022","unstructured":"Wu, M., et al., Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation. Journal of Hematology & Oncology, 2022. 15(1): p. 24.","journal-title":"Journal of Hematology & Oncology"},{"key":"ref95","author":"Gibran Hemani BE","year":"2025","unstructured":"Gibran Hemani, B.E., Tom Palmer, Rita Rasteiro. ieugwasr: Interface to the 'OpenGWAS' Database API. 2025; Available from: https:\/\/github.com\/MRCIEU\/ieugwasr."},{"issue":"1","key":"ref96","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/1471-2105-8-428","article-title":"Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool 'CubeX'","volume":"8","author":"Gaunt TR","year":"2007","unstructured":"Gaunt, T.R., S. Rodr\u00edguez, and I.N.M. Day, Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool 'CubeX'. BMC Bioinformatics, 2007. 8(1): p. 428.","journal-title":"BMC Bioinformatics"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9656350\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9656350\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:39:58Z","timestamp":1785260398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9656350\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":96,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9656350\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,7,28]]},"subtype":"preprint"}}